NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...
The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.
The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results